BR9708068A - Método de inibição da replicação de citomegalovìrus em um mamìfero, composição anti- citomegalovìrus e composto. - Google Patents

Método de inibição da replicação de citomegalovìrus em um mamìfero, composição anti- citomegalovìrus e composto.

Info

Publication number
BR9708068A
BR9708068A BR9708068-3A BR9708068A BR9708068A BR 9708068 A BR9708068 A BR 9708068A BR 9708068 A BR9708068 A BR 9708068A BR 9708068 A BR9708068 A BR 9708068A
Authority
BR
Brazil
Prior art keywords
cytomegaloviruses
replication
mammal
inhibiting
compound composition
Prior art date
Application number
BR9708068-3A
Other languages
English (en)
Inventor
Haoulun Jin
Laval Chung-Kong Chan
Wei Wang
Tomislav Stefanac
Tarek S Mansour
Paul Nguyen-Ba
Jean-Francois Lavellee
Guy Falardeau
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of BR9708068A publication Critical patent/BR9708068A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

<B>"MéTODO DE INIBIçãO DA REPLICAçãO DE CITOMEGALOVìRUS EM UM MAMìFERO, COMPOSIçãO ANTI-CITOMEGALOVìRUS E COMPOSTO"<D>. A presente invenção se refere a compostos heterocíclicos, mais particularmente compostos de naftiridina dotados de atividade antiviral. Em particular, compostos de fórmula (I), na qual B, W, X, Y, R~ 1~, R~ 2~, R~ 3~, R~ 4~ e n são tal como aqui definidos, são utilizáveis na terapia e na profilaxia da infecção do citomegalovírus (CMV) em mamíferos.
BR9708068-3A 1996-03-15 1997-03-14 Método de inibição da replicação de citomegalovìrus em um mamìfero, composição anti- citomegalovìrus e composto. BR9708068A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9605437.4A GB9605437D0 (en) 1996-03-15 1996-03-15 Cytomegalovirus inhibiting compounds
PCT/CA1997/000182 WO1997034894A1 (en) 1996-03-15 1997-03-14 Naphthyridine derivatives and their analogues inhibiting cytomegalovirus

Publications (1)

Publication Number Publication Date
BR9708068A true BR9708068A (pt) 2000-01-04

Family

ID=10790420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708068-3A BR9708068A (pt) 1996-03-15 1997-03-14 Método de inibição da replicação de citomegalovìrus em um mamìfero, composição anti- citomegalovìrus e composto.

Country Status (12)

Country Link
EP (1) EP0984967B1 (pt)
JP (1) JP2001515464A (pt)
CN (1) CN1069643C (pt)
AT (1) ATE260279T1 (pt)
AU (1) AU722650B2 (pt)
BR (1) BR9708068A (pt)
CA (1) CA2250320A1 (pt)
DE (1) DE69727838D1 (pt)
GB (2) GB9605437D0 (pt)
TW (1) TW480258B (pt)
WO (1) WO1997034894A1 (pt)
ZA (1) ZA972292B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711257D0 (en) 1997-05-30 1997-07-30 Smithkline Beecham Plc Novel compounds
CN1283995A (zh) 1997-12-11 2001-02-14 生化制药有限公司 抗病毒化合物
AU777040B2 (en) * 1999-02-22 2004-09-30 Shire Biochem Inc. (1,8) naphthyridine derivatives having antiviral activity
DE19912638A1 (de) * 1999-03-20 2000-09-21 Bayer Ag Naphthylcarbonsäureamid-substituierte Sulfonamide
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
WO2002051413A2 (en) * 2000-12-27 2002-07-04 Shire Biochem Inc. Macrocyclic anti-viral compounds
WO2002060382A2 (en) 2001-01-19 2002-08-08 Smithkline Beecham Corporation Novel compounds and uses thereof
EP1669348A4 (en) * 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
US20080207677A1 (en) * 2004-12-31 2008-08-28 Gpc Biotech Ag Napthyridine Compounds As Rock Inhibitors
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
KR20100015897A (ko) 2007-04-27 2010-02-12 에자이 알앤드디 매니지먼트 가부시키가이샤 헤테로환 치환 피리딘 유도체의 염 또는 그의 결정
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
EP2155748A1 (en) * 2007-05-15 2010-02-24 Boehringer Ingelheim International GmbH Urotensin ii receptor antagonists
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
BR112015011094A2 (pt) 2012-11-20 2017-07-11 Hoffmann La Roche 1,6-naftiridinas substituídas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
JPH02237922A (ja) * 1989-01-24 1990-09-20 Green Cross Corp:The 抗ウィルス剤
AU5449590A (en) * 1989-04-28 1990-11-29 Daiichi Pharmaceutical Co., Ltd. Anti-hiv drug
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
AU5447094A (en) * 1992-10-21 1994-05-09 Regents Of The University Of Michigan, The Polysubstituted benzimidazoles as antiviral agents
DE4303657A1 (de) * 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
DE4331135A1 (de) * 1993-09-14 1995-03-16 Bayer Ag Neue antiviral wirksame valinhaltige Pseudopeptide
US5543413A (en) * 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
US5773027A (en) * 1994-10-03 1998-06-30 Michael G. Bergeron Liposomes encapsulating antiviral drugs
ES2211965T3 (es) * 1995-08-02 2004-07-16 Darwin Discovery Limited Quinolonas y su utilizacion terapeutica.

Also Published As

Publication number Publication date
CN1069643C (zh) 2001-08-15
TW480258B (en) 2002-03-21
AU1918797A (en) 1997-10-10
ATE260279T1 (de) 2004-03-15
WO1997034894A1 (en) 1997-09-25
CN1218473A (zh) 1999-06-02
JP2001515464A (ja) 2001-09-18
ZA972292B (en) 1997-10-16
GB9819782D0 (en) 1998-11-04
AU722650B2 (en) 2000-08-10
GB9605437D0 (en) 1996-05-15
CA2250320A1 (en) 1997-09-25
DE69727838D1 (de) 2004-04-01
EP0984967A1 (en) 2000-03-15
GB2326412A (en) 1998-12-23
EP0984967B1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
BR9708068A (pt) Método de inibição da replicação de citomegalovìrus em um mamìfero, composição anti- citomegalovìrus e composto.
BR9815166A (pt) &#34;método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral&#34;
ATE231839T1 (de) Polyaromatische antivirale zusammensetzungen
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
MX9304638A (es) Composicion para tratar e inhibir las ulceras gastricas y duodenales.
FI945363A (fi) Uusia merkaptoasetyyliamidopyridatso (1,2)pyridatsiini-, pyratsolo(1,2)pyridatsiini-, pyridatso (1,2-a)(1,2)diatsepiini- ja pyratsolo(1,2-a)(1,2)diatsepiinijohdannaisia, jotka ovat käyttökelpoisia enkefalisaasin ja ACE:n estäjinä
NZ502988A (en) 5-Acetamido-4-amino-2-propionyloxy-6-isopropoxy-1-cyclohexene useful for treating influenza
DE69413167T2 (de) Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
CA2114727A1 (en) Quinoline Derivatives as Immunostimulants
CA2361614A1 (en) Compositions for treating inflammatory response
HU9203286D0 (en) Inflammation inhibiting hydrosame acids and n-hydroxi-ureas
NO933611L (no) Anti-tumor- og anti-psoriatiske midler
AU9066498A (en) Substituted 6-alkylphenanthridines
ATE172985T1 (de) Sulfonamidaminomethylenderivate als immunsuppressiva
CA2144344A1 (en) Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents
DE69619259T2 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
NO972905L (no) Tienoksasinon-derivater anvendelige som antivirusmidler
NO961900D0 (no) Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid
CA2261802A1 (en) Use of xanomeline for treating bipolar disorder
TR199902820T2 (xx) Multisiklik eritromisin t�revleri.
GR3019075T3 (en) Inhibitor of herpes simplex viral thymidine kinase
DE69428127D1 (de) Schädlingsbekämpfungsmittel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]